Compare Enveric Biosciences Inc (ENVB) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Uranium Energy Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 666.2× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Uranium Energy Corp for 37 Days on average.
| ENVB | UEC | |
|---|---|---|
Market Cap | $6.80M | $4.53B |
Volume | 64,867 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $10.80 | $20.14 |
52-Week Low | $1.27 | $9.04 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | -$1.49M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a net income margin of -368.62% and has missed earnings expectations in recent quarters. However, the company is expanding production capacity with two operational mines and benefits from growing U.S. government demand for domestic uranium.
While analyst consensus remains strongly bullish with an 87.5% buy rating and $16.06 price target, fundamental challenges persist including negative cash flow from operations and unproven production sustainability. The stock faces execution risks as it scales operations, but long-term uranium demand tailwinds provide potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
